Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 18Gynecologic 7Thoracic 4Genitourinary 3Endocrine 3Dermatologic 3Sarcoma 2CNS 2Plasma cell 1Other hematologic neoplasm 1Myeloid 1Head & Neck 1Breast 1

Conditions

Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Somatostatinoma 1Neoplasm Metastasis 1Multiple Endocrine Neoplasia Type 1 1Carcinoid Tumor 1Adenocarcinoma, Follicular 1

Interventions

Everolimus 25Magnetic Resonance Spectroscopy 13pembrolizumab 12pasireotide 12Sunitinib 11Octreotide 11lanreotide 10cabozantinib 10lenvatinib 8Sorafenib 8Cisplatin 8Temozolomide 7Etoposide 7Bevacizumab 7pazopanib 6Paclitaxel 6Nivolumab 6Doxorubicin 6Carboplatin 6Capecitabine 6vandetanib 5gallium Ga 68 dotatate 5Specimen Handling 5trametinib 4lutetium Lu 177 dotatate 4dabrafenib 4Mitotane 4Iodine-131 4telotristat ethyl 3surufatinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × aflibercept × Endocrine × Clear all
NCT01782443 2023-08-14

Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors

Dana-Farber Cancer Institute

Phase 2 Completed
19 enrolled 11 charts
Endocrine

Carcinoid Tumor, Neoplasm Metastasis

NCT02101918 2020-03-23

Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Completed
22 enrolled 10 charts
Endocrine

Somatostatinoma, Multiple Endocrine Neoplasia Type 1

NCT00729157 2017-03-15

Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy

National Cancer Institute (NCI)

Phase 2 Completed
41 enrolled 10 charts
EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡